A RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND, ASCENDING-DOSE, SAFETY STUDY OF CC-220 IN SUBJECTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS

被引：1

作者：

Werth, V. P. ^{[1
]}

Furie, R. ^{[2
]}

Korish, S. ^{[3
]}

Weiswasser, M. ^{[3
]}

Azaryan, A. ^{[3
]}

Schafer, P. H. ^{[3
]}

Delev, N. ^{[3
]}

Choi, S. ^{[3
]}

Hough, D. ^{[3
]}

机构：

[1] Univ Penn, Sch Med, Philadelphia, PA 19104 USA

[2] Northwell Hlth, Great Neck, NY USA

[3] Celgene Corp, Summit, NJ USA

来源：

ANNALS OF THE RHEUMATIC DISEASES | 2017年 / 76卷

关键词：

D O I：

10.1136/annrheumdis-2017-eular.3546

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

SAT0255

引用

页码：870 / 871

页数：2

共 50 条

[41] Safety, pharmacokinetics, and pharmacodynamics of RSLV-132, an RNase-Fc fusion protein in systemic lupus erythematosus: a randomized, double-blind, placebo-controlled study
Burge, D. J.
Eisenman, J.
Byrnes-Blake, K.
Smolak, P.
Lau, K.
Cohen, S. B.
Kivitz, A. J.
Levin, R.
Martin, R. W.
Sherrer, Y.
Posada, J. A.
LUPUS, 2017, 26 (08) : 825 - 834
[42] The effect of propiverine on cardiac safety in healthy female subjects: A double-blind, placebo-controlled randomized study
Eckl, KM
Tsvitbaum, NM
Donath, F
Biletsky, SV
Sydorchuk, LP
AMERICAN JOURNAL OF HYPERTENSION, 2003, 16 (05) : 262A - 262A
[43] STUDY DESIGN FOR A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF REPOSITORY CORTICOTROPIN INJECTION IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS DESPITE MODERATE-DOSE CORTICOSTEROIDS
Askanase, Anca
Zhao, Enxu
Zhu, Julie
Connolly-Strong, Erin
Furie, Richard
ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 : 766 - 766
[44] Double blind, randomized, placebo controlled pilot study of leflunomide in systemic lupus erythematosus (SLE)
Tam, LS
Li, EK
Wong, CK
Lam, CWK
Szeto, CC
ANNALS OF THE RHEUMATIC DISEASES, 2004, 63 : 213 - 213
[45] Deucravacitinib, a Tyrosine Kinase 2 Inhibitor, in Systemic Lupus Erythematosus: A Phase II, Randomized, Double-Blind, Placebo-Controlled Trial
Morand, Eric
Pike, Marilyn
Merrill, Joan T.
van Vollenhoven, Ronald
Werth, Victoria P.
Hobar, Coburn
Delev, Nikolay
Shah, Vaishali
Sharkey, Brian
Wegman, Thomas
Catlett, Ian
Banerjee, Subhashis
Singhal, Shalabh
ARTHRITIS & RHEUMATOLOGY, 2023, 75 (02) : 242 - 252
[46] A double-blind, randomized, placebo-controlled, phase II trial of baricitinib for systemic lupus erythematosus: how to optimize lupus trials to examine effects on cutaneous lupus erythematosus
Werth, V. P.
Merrill, J. T.
BRITISH JOURNAL OF DERMATOLOGY, 2019, 180 (05) : 964 - 965
[47] Dehydroepiandrosterone treatment of women with mild-to-moderate systemic lupus erythematosus - A multicenter randomized, double-blind, placebo-controlled trial
Chang, DM
Lan, JL
Lin, HY
Luo, SF
ARTHRITIS AND RHEUMATISM, 2002, 46 (11): : 2924 - 2927
[48] Safety and pharmacokinetics of the nonnucleoside polymerase inhibitor, HCV-796: Results of a randomized, double-blind, placebo-controlled, ascending single-dose study in healthy subjects
Chandra, P.
Raible, D.
Moyer, L.
Harper, D.
Speth, J.
Villano, S.
Fruncillo, R.
JOURNAL OF HEPATOLOGY, 2006, 44 : S208 - S209
[49] A randomized, double-blind, placebo-controlled, single ascending dose study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of CBP-201 administered to healthy adult subjects
Royal, Mike A.
White, Jeffery
Snyder, Ben
Wei, Zheng
Pan, Wubin
Wang, Junying
Sansone, Kenneth J.
Yang, Xin
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2020, 83 (06) : AB159 - AB159
[50] BARICITINIB IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE): RESULTS FROM A PHASE 2, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY
Wallace, D. J.
Furie, R. A.
Tanaka, Y.
Kalunian, K. C.
Mosca, M.
Petri, M. A.
Dorner, T.
Cardiel, M. H.
Bruce, I. N.
Gomez, E.
Carmack, T.
Janes, J. M.
Linnik, M. D.
Silk, M.
Hoffman, R.
ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 59 - 59

← 1 2 3 4 5 →